HH-GV-678，一种新型的Bcr-Abl选择性抑制剂，其性能优于伊马替尼，并能有效克服伊马替尼耐药性。 - Suppr

Suppr

超能文献

HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance.

作者信息

Luo H, Quan H, Xie C, Xu Y, Fu L, Lou L

出版信息

Leukemia. 2010 Oct;24(10):1807-9. doi: 10.1038/leu.2010.169. Epub 2010 Aug 12.

DOI:10.1038/leu.2010.169

PMID:20703259

Abstract

摘要

相似文献

HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance.

Leukemia. 2010 Oct;24(10):1807-9. doi: 10.1038/leu.2010.169. Epub 2010 Aug 12.

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Cancer Res. 2013 Sep 15;73(18):5775-86. doi: 10.1158/0008-5472.CAN-13-1318. Epub 2013 Jul 25.

Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.

J Zhejiang Univ Sci B. 2012 Nov;13(11):867-74. doi: 10.1631/jzus.B1200021.

Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways.

J Cancer Res Clin Oncol. 2015 Feb;141(2):283-93. doi: 10.1007/s00432-014-1820-2. Epub 2014 Sep 14.

HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.

Cancer Lett. 2014 Jun 28;348(1-2):50-60. doi: 10.1016/j.canlet.2014.03.012. Epub 2014 Mar 18.

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.

Clin Cancer Res. 2005 Jul 1;11(13):4941-7. doi: 10.1158/1078-0432.CCR-04-2601.

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).

Eur J Pharmacol. 2021 Apr 15;897:173944. doi: 10.1016/j.ejphar.2021.173944. Epub 2021 Feb 11.

MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.

Cancer Lett. 2015 Jan 28;356(2 Pt B):597-605. doi: 10.1016/j.canlet.2014.10.006. Epub 2014 Oct 8.

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.

Blood. 2007 Jan 1;109(1):306-14. doi: 10.1182/blood-2006-03-013250. Epub 2006 Sep 5.

Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.

Acta Pharmacol Sin. 2014 Mar;35(3):401-9. doi: 10.1038/aps.2013.180. Epub 2014 Feb 3.

引用本文的文献

Real-world comparison of flumatinib and nilotinib as first-line therapy for patients with chronic phase chronic myeloid leukemia: a multicenter retrospective study.

Ther Adv Med Oncol. 2025 Apr 29;17:17588359251335905. doi: 10.1177/17588359251335905. eCollection 2025.

[Advances in basic and clinical research of flumatinib].

Zhonghua Xue Ye Xue Za Zhi. 2024 Jun 14;45(6):621-624. doi: 10.3760/cma.j.cn121090-20231211-00304.

Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia.

Haematologica. 2024 Dec 1;109(12):3965-3974. doi: 10.3324/haematol.2023.284892.

Studies on the inhibitory effect of isavuconazole on flumatinib metabolism and .

Front Pharmacol. 2023 May 4;14:1168852. doi: 10.3389/fphar.2023.1168852. eCollection 2023.

Basic and clinical study of efficacy and adverse effects of flumatinib in Ph ALL.

Front Pharmacol. 2023 May 5;14:1178393. doi: 10.3389/fphar.2023.1178393. eCollection 2023.

Efficacy of Flumatinib in CML Patients with F359V/C Mutation.

Indian J Hematol Blood Transfus. 2023 Apr;39(2):344-346. doi: 10.1007/s12288-022-01585-3. Epub 2022 Oct 17.

[Clinical observation of flumatinib combined with induction chemotherapy and sequential allogeneic hematopoietic stem cell transplantation in the treatment of 6 patients with newly diagnosed Ph(+) acute lymphocytic leukemia].

Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):169-172. doi: 10.3760/cma.j.issn.0253-2727.2023.02.017.

[Clinical efficacy and safety of flumatinib combined with multidrug chemotherapy in the treatment of 12 cases with Ph(+) acute lymphoblastic leukemia].

Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):858-861. doi: 10.3760/cma.j.issn.0253-2727.2021.10.011.

Effect of high-fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects.

Cancer Chemother Pharmacol. 2020 Sep;86(3):339-346. doi: 10.1007/s00280-020-04117-w. Epub 2020 Aug 5.

CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance.

Biomedicines. 2018 Mar 8;6(1):31. doi: 10.3390/biomedicines6010031.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验